Key Points
- Insider sale: Zimmer Biomet insider Kevin Thornal sold 5,691 shares for approximately $528,978 at an average price of $92.95.
- Financial performance: The company exceeded quarterly expectations, reporting adjusted EPS of $2.07 versus a $2.01 consensus and revenue of $2.18 billion, up 4.8% year over year.
- Market view: Analysts maintain a consensus “Hold” rating with an average price target of $104.42. Zimmer Biomet also declared a quarterly dividend of $0.24 per share, implying a 1.0% annualized yield.
Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Get Free Report) insider Kevin Thornal sold 5,691 shares of the company's stock in a transaction on Friday, September 11th. The shares were sold at an average price of $92.95, for a total value of $528,978.45. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Zimmer Biomet Trading Up 2.0%
Zimmer Biomet stock opened at $98.45 on Wednesday. Zimmer Biomet Holdings, Inc. has a one year low of $79.12 and a one year high of $106.88. The business's fifty day moving average is $95.86 and its 200 day moving average is $91.44. The stock has a market capitalization of $18.78 billion, a PE ratio of 23.95, a price-to-earnings-growth ratio of 1.82 and a beta of 0.47. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.69 and a quick ratio of 0.94.
Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.01 by $0.06. The business had revenue of $2.18 billion for the quarter, compared to analysts' expectations of $2.13 billion. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The business's revenue for the quarter was up 4.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current year.
Zimmer Biomet Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a dividend of $0.24 per share. The ex-dividend date is Wednesday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. Zimmer Biomet's dividend payout ratio is 23.36%.
Analysts Set New Price Targets
A number of equities research analysts have commented on the stock. Zacks Research raised shares of Zimmer Biomet from a "strong sell" rating to a "hold" rating in a research report on Tuesday, August 25th. Stifel Nicolaus raised their price target on Zimmer Biomet from $105.00 to $110.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. Canaccord Genuity Group raised their price target on Zimmer Biomet from $83.00 to $100.00 and gave the stock a "hold" rating in a research note on Monday, August 10th. Wall Street Zen cut Zimmer Biomet from a "buy" rating to a "hold" rating in a research report on Saturday, August 8th. Finally, BMO Capital Markets reissued a "market perform" rating and issued a $96.00 target price on shares of Zimmer Biomet in a report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $104.42.
Read Our Latest Analysis on Zimmer Biomet
Institutional Trading of Zimmer Biomet
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Main Management ETF Advisors LLC lifted its stake in Zimmer Biomet by 1.0% during the fourth quarter. Main Management ETF Advisors LLC now owns 10,962 shares of the medical equipment provider's stock valued at $986,000 after buying an additional 112 shares in the last quarter. Citizens National Bank Trust Department raised its holdings in shares of Zimmer Biomet by 17.6% during the first quarter. Citizens National Bank Trust Department now owns 941 shares of the medical equipment provider's stock valued at $85,000 after acquiring an additional 141 shares during the period. TD Private Client Wealth LLC lifted its position in shares of Zimmer Biomet by 15.3% in the 4th quarter. TD Private Client Wealth LLC now owns 1,152 shares of the medical equipment provider's stock valued at $104,000 after acquiring an additional 153 shares in the last quarter. Leonteq Securities AG grew its position in Zimmer Biomet by 5.3% during the 1st quarter. Leonteq Securities AG now owns 3,062 shares of the medical equipment provider's stock worth $277,000 after purchasing an additional 153 shares in the last quarter. Finally, Envestnet Portfolio Solutions Inc. lifted its holdings in shares of Zimmer Biomet by 5.5% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 3,133 shares of the medical equipment provider's stock valued at $282,000 after purchasing an additional 162 shares in the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.
About Zimmer Biomet
(
Get Free Report)
Zimmer Biomet Holdings, Inc (NYSE:ZBH) is a medical technology company that develops, manufactures and markets products designed to treat musculoskeletal conditions. Its portfolio includes orthopedic implants and related systems for hip, knee, shoulder and other joint replacements, as well as products used in sports medicine, extremity care and trauma procedures.
The company also provides robotic- and computer-assisted surgical technologies, digital solutions and other tools intended to support orthopedic procedures and patient care.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
